Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Supernus Pharmaceuticals Q3 2025 Earnings Call - Strong Growth Amid Onapco Supply Constraints
Supernus Pharmaceuticals reported solid Q3 2025 results propelled by four growth products—Qelbree, Gocovri, Zurzuvae, and the newly launched Onapco—which together contributed approximately 78% of tota...
- Supernus's four growth products—Qelbree, Gocovri, Zurzuvae, and Onapco—accounted for about 78% of Q3 2025 revenues.
- Onapco net sales jumped to $6.8 million in Q3 from $1.6 million in Q2, showing strong early launch momentum.
- Supplier constraints on Onapco cartridges forced prioritization of current patients, pausing new starts temporarily.
- +17 more takeaways
Latham Group Q3 2025 Earnings Call - Market Outperformance and Strong Margin Expansion Despite Flat Industry
Latham Group delivered a robust third quarter in 2025, boasting a 7.6% increase in net sales and a 28.5% surge in adjusted EBITDA, underscoring the company's ability to outperform a flat to slightly d...
- Latham Group's Q3 2025 net sales increased 7.6% year-over-year, significantly outpacing the flat to slightly down US in-ground pool market.
- Adjusted EBITDA grew 28.5%, reflecting substantial operating leverage and margin expansion, with adjusted EBITDA margin rising 390 basis points to 23.7%.
- Fiberglass pools accounted for approximately 75% of Latham's full-year 2025 in-ground pool sales, driven by fast installation and lower labor requirements.
- +12 more takeaways
Corvus Pharmaceuticals Q3 2025 Earnings Call - Soquelitinib Advances with Promising Safety and Efficacy Data, Phase II Trial Set for Early 2026
Corvus Pharmaceuticals reported a substantial advancement in its lead asset, soquelitinib, focused on atopic dermatitis (AD) and peripheral T-cell lymphoma (PTCL). The company closed enrollment for th...
- Q3 2025 net loss was $10.2 million, a significant improvement from $40.2 million in Q3 2024 due to reduced warrant liability losses.
- Research & Development expenses rose to $8.5 million from $5.2 million year-over-year, driven by clinical and manufacturing costs for soquelitinib and increased personnel costs.
- Corvus holds $65.7 million in cash and equivalents as of September 30, 2025, with a cash runway expected into Q4 2026.
- +7 more takeaways
Tarsus Q3 2025 Earnings Call - XDEMVY Sets New Standard with Blockbuster Plus Potential
Tarsus delivered a strong Q3 2025, led by XDEMVY’s exceptional market launch, generating $119 million in net product sales, with over 103,000 bottles dispensed and a rapidly growing prescriber base su...
- XDEMVY delivered $119 million net sales in Q3 with over 103,000 bottles dispensed, marking a double-digit growth quarter.
- More than 20,000 eye care professionals have prescribed XDEMVY, with 20% growth in weekly prescribers and 30% in frequent prescribers.
- Doctors report changing practice patterns, increasingly screening and treating Demodex blepharitis (DB) across broader patient segments, supported by new meibomian gland disease data.
- +12 more takeaways
MNTN Q3 2025 Earnings Call - Accelerating Growth Through Democratizing Performance TV Advertising
MNTN reported a strong Q3 2025 with revenue at $70 million, up 31% year-over-year excluding divestitures, and positive GAAP net income of $6.4 million signaling its first profitability in four years. ...
- MNTN Q3 2025 revenue increased 31% year-over-year to $70 million excluding Maximum Effort divestiture impact.
- First GAAP profitable quarter in four years with $6.4 million net income and $0.09 EPS.
- Adjusted EBITDA grew 53% year-over-year to $16 million with a margin improvement to 22.8%.
- +12 more takeaways
Niagen Biosciences Inc. Q3 2025 Earnings Call - Record Growth Fueled by E-commerce and Strategic Healthcare Partnerships
Niagen Biosciences reported a strong third quarter of 2025, delivering $34 million in revenue, up 33% year-over-year, and net income of $4.6 million, more than doubling last year's figure. The company...
- Q3 2025 revenue hit $34 million, a 33% year-over-year increase, with net income of $4.6 million versus $1.9 million last year.
- E-commerce sales reached $19 million, up 29%, anchoring growth alongside a 109% jump in distribution revenue to $7 million, fueled by a new partner network of 8,000 healthcare practitioners.
- Niagen Plus at-home injection kits launched, initially available via prescription at clinics; plans underway to enable telehealth prescriptions and DTC sales within two quarters.
- +7 more takeaways
Rigel Pharmaceuticals Q3 2025 Earnings Call - Robust Commercial Growth and R289 Clinical Progress Drive Upward Guidance
Rigel Pharmaceuticals reported a blockbuster third quarter in 2025, powered by a 65% year-over-year surge in net product sales to $64.1 million and a strategic ramp-up in their hematology and oncology...
- Rigel reported third quarter 2025 total revenue of $69.5 million, with net product sales reaching a record $64.1 million, a 65% increase year-over-year.
- The company raised its full-year 2025 revenue guidance to $285-$290 million, reflecting confidence from commercial momentum.
- TAVALISSE sales led growth with $44.7 million in Q3, up 70% year-over-year, driven by increased demand and favorable gross-to-net dynamics.
- +12 more takeaways
MasterBrand Q3 2025 Earnings Call - Navigating Tariffs and Market Headwinds While Advancing Merger Integration
MasterBrand reported a 3% decline in net sales to $699 million in Q3 2025, reflecting mid to high single-digit market contractions that were partially offset by pricing and share gains. Adjusted EBITD...
- MasterBrand's Q3 net sales declined 3% year-over-year to $699 million, reflecting mid to high single-digit market contractions.
- Adjusted EBITDA decreased 13.3% to $90.6 million, with margins compressed by lower volumes, fixed cost absorption challenges, and tariffs.
- New Section 232 tariffs on lumber, cabinets, and vanities became effective October 14, with a 25% rate initially and a planned 50% increase in Q1 2026.
- +12 more takeaways
Arteris Q3 2025 Earnings Call - AI and Chiplet Demand Propel 24% Contract Growth Amid Robust Ecosystem Expansion
Arteris reported a strong Q3 2025, with annual contract value plus royalties hitting a record $74.9 million, up 24% year-over-year, driven largely by the surge in AI applications accounting for over h...
- Arteris achieved a record $74.9 million in annual contract value plus royalties in Q3 2025, reflecting 24% year-over-year growth, driven by heightened AI application demand.
- AI-related licensing accounted for over 50% of Arteris' licensing dollars in the quarter, underscoring AI's dominance in their design win pipeline.
- Altera selected Arteris' IP portfolio, including Encore, FlexGen, and Magillem platforms, to streamline FPGA and SoC FPGA designs across multiple high-end applications.
- +12 more takeaways
Crexendo Q3 2025 Earnings Call - Robust 12% Revenue Growth Fueled by AI Innovation and Platform Expansion
Crexendo reported a strong third quarter with 12% year-over-year revenue growth driven by a 28% surge in software solutions and an 8% increase in service revenue. The company now supports over 7 milli...
- Crexendo delivered 12% year-over-year consolidated revenue growth to $17.5 million in Q3 2025.
- Software solutions revenue surged 28% to $7.5 million, driving margin expansion with 74% gross margin in this segment.
- Service revenue grew 8% to $8.6 million, reflecting strong retail team execution and faster conversion to recurring revenue.
- +17 more takeaways